A Trial on Probiotics in Preventing Hirschsprung's Disease Associated Entercolitis
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
Enterocolitis(EC) is the most common and serious postoperative complication of Hirschsprung's
disease(HD) with high morbidity and mortality. Probiotics are live microbes that, when
administered in adequate amounts, confer health benefit to the host.Based on this previous
knowledge on the beneficial effects of probiotics during pro-inflammatory conditions of the
gastrointestinal tract, investigators hypothesized that oral probiotics could decrease the
incidence and severity of Hirschsprung's disease associated enterocolitis(HAEC).Investigators
conducted a prospective, multicenter, randomized and controlled trial to assess whether oral
probiotics could decrease the incidence and severity of Hirschsprung's disease associated
enterocolitis(HAEC).